Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The...

Full description

Saved in:
Bibliographic Details
Main Authors: Ayşe Demirci, Cemil Bilir, Burcu Gülbağcı, İlhan Hacıbekiroğlu, İbrahim V. Bayoğlu, İrem Bilgetekin, Sinan Koca, Havva Y. Çınkır, Nadiye Akdeniz, Deniz Gül, Ceyhun Varım, Umut Demirci, Berna Öksüzoğlu
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
R
Q
Online Access:https://doaj.org/article/2f1961a10d9b47f5b41b353c34cd4036
Tags: Add Tag
No Tags, Be the first to tag this record!